Salute e Benessere

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in…

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myelomaSarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is the first global phase 3 study to evaluate the SC administration of a cancer treatment via an OBDSOBDS is an alternative delivery method designed to improve the patient experience and...
Nasdaq GlobeNewswire
09/01/2025

Holistic care for senior citizen parents of NRIs: Policybazaar and insurer…

This new initiative rolls out an umbrella of services aimed at easing the concerns of NRIs, 40-60% of whom hail from the Gulf region and the rest majorly from the US and Canada. Notably, 50% of these NRIs prioritize securing the well-being of their elderly family members in India. Our research indicates that more than 70% of the NRIs expressed the need for support in services such as right doctor or hospital identification in India and thereafter with claims paperwork. This new initiative…
PR Newswire
09/01/2025

Holistic care for senior citizen parents of NRIs: Policybazaar and insurer…

This new initiative rolls out an umbrella of services aimed at easing the concerns of NRIs, 40-60% of whom hail from the Gulf region and the rest majorly from the US and Canada. Notably, 50% of these NRIs prioritize securing the well-being of their elderly family members in India. Our research indicates that more than 70% of the NRIs expressed the need for support in services such as right doctor or hospital identification in India and thereafter with claims paperwork. This new initiative…
PR Newswire
09/01/2025

Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by…

Key Takeaways from the Mild Cognitive Impairment Market Report Key Takeaways from the Mild Cognitive Impairment Market Report Discover which therapies are expected to grab the major mild cognitive impairment market share @ Mild Cognitive Impairment Market Report Mild Cognitive Impairment Overview Mild cognitive impairment (MCI) refers to a noticeable decline in cognitive abilities, such as memory and thinking, that is more severe than expected for a person's age but not severe...
PR Newswire
08/01/2025

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) Listing market: Euronext GrowthISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of voting rights 12/31/2024100,093,87388,660,539For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,[email protected] Patricia Sosa Navarro, Chief of Staff to the...
Nasdaq GlobeNewswire
08/01/2025

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3…

th, 2025 DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study EPITOPE OLE data demonstrates continued improvement in treatment benefit of VIASKIN® Peanut patch in toddlers 1 – 3 years through 36 months 68.2% of subjects completed the oral food challenge (~12-14 peanut kernels) without meeting stopping criteria, compared to 30.7% at month 12No treatment-related anaphylaxis or serious treatment-related Treatment-Emergent Adverse...
Nasdaq GlobeNewswire
08/01/2025

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Investigational new drug (IND) applications for initiating first-in-human studies for ZW220 and ZW251 in solid tumors anticipated in 2025IND applications for initiating first-in-human studies for ZW209 and ZW1528 anticipated in 2026Phase 3 HERIZON-GEA-01 top-line results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) are expected 2Q-2025, with potential supplemental biologics license application (sBLA) by Jazz Pharmaceuticals...
Nasdaq GlobeNewswire
08/01/2025

DIOSynVax Announces a new Advisory Board as it drives the clinical development…

During the COVID-19 pandemic DIOSynVax pivoted to use it computational technology to develop a broadly protective vaccine against SARS, SARS-CoV-2 and related coronaviruses. Following extensive evaluation for safety and efficacy in animals (Vishwanath et al, Nature Biomedical Engineering 2023), the "First-in-Human" Phase 1 clinical trial of this revolutionary digitally engineered vaccine antigen was conducted at the NIHR Southampton and Cambridge Clinical Research Facilities and…
PR Newswire
08/01/2025

Global Pain Treatment Market to Reach $144.2 Billion by 2029

This report explores the market for conventional and alternative pain treatments, analyzing current trends, growth potential, leading companies, and emerging technologies. It segments the market by treatment type (drugs such as analgesics and medical cannabis, and devices such as stimulators) and application (orthopedic, surgical, migraine and cancer). The study also provides regional analysis of markets in North America, Europe, and Asia-Pacific, with projections to 2029. This report…
PR Newswire
08/01/2025

BBI Solutions appoints Alexander A. Socarrás as Chief Executive Officer

Succeeding Mario, with immediate effect, is Alexander A. Socarrás. Alex is a highly experienced diagnostics industry leader with over 30 years of experience in senior roles at Siemens Healthineers, Ortho Clinical Diagnostics, Bayer Healthcare and Roche Diagnostics, most recently serving as Executive Vice President of Global Commercial Operations at Siemens Healthineers' diagnostics business. Alex holds a Bachelor of Science in Chemistry and an MBA, and has lived and worked in the United States…
PR Newswire
08/01/2025

Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study, published in Nature Medicine on 8 January 2025, demonstrates the therapeutic use of a precision gene editing technology called base editing.Stargardt disease affects 1 in 6,500 individuals and often results in legal blindness. There is currently no effective treatment available. The research team,...
Nasdaq GlobeNewswire
08/01/2025

Tecan meets revised sales outlook for fiscal year 2024

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan meets revised sales outlook for fiscal year 2024Männedorf, Switzerland, January 8, 2025 –In a trading statement, the Tecan Group (SIX Swiss Exchange: TECN) today published unaudited preliminary sales results for fiscal year 2024, meeting the revised sales outlook provided on October 16, 2024. The year 2024 was marked by a challenging market environment for Tecan. Reduced spending in the...
Nasdaq GlobeNewswire
08/01/2025

HOOKIPA Pharma Inc - FORM 8 (OPD)

NEW YORK and VIENNA, Austria, Jan.08, 2025(GLOBE NEWSWIRE) --FORM 8 (OPD)PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER Rules 8.1 and 8.2 of the Takeover Code (the “Code”)1. KEY INFORMATION(a) Full name of discloser: HOOKIPA Pharma Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and...
Nasdaq GlobeNewswire
08/01/2025

Cell Therapy Technologies Market to Hit US$ 6.80 Billion by 2029 with 11.0% CAGR…

Browse in-depth TOC on "Cell Therapy Technologies Market"516 - Tables55 - Figures463 - Pages Browse in-depth TOC on "Cell Therapy Technologies Market" 516 - Tables 55 - Figures 463 - Pages The product segment is segmented into media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products. media, sera, and reagents cell therapy technologies segment dominated product segments owing to various…
PR Newswire
08/01/2025

ClearCut Medical Announces Results of a Post Marketing ClearCoast™ Study…

The study aimed primarily to compare retreatment proportion within and between study groups with accordance to the SSO-ASTRO guideline. The secondary endpoint compared ClearCoast™ and the Standard of Care (SoC) diagnostic ability to detect positive margins intraoperatively, as well as the total excised breast tissue volume between study groups. The study aimed primarily to compare retreatment proportion within and between study groups with accordance to the SSO-ASTRO guideline. The secondary...
PR Newswire
08/01/2025

ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk…

The breast cancer risk analysis technology from Biomediq enables automatic, computer-based analysis of 2D and 3D mammograms for analysis of future risk of breast cancer. It is built around a Mammographic Texture Risk biomarker that recognises tissue heterogeneity, often called mammographic texture, associated with both short- and long-term risk of breast cancer. The breast cancer risk analysis technology from Biomediq enables automatic, computer-based analysis of 2D and 3D mammograms for...
PR Newswire
08/01/2025

Immunovia AB (Publ) presents Nomination Committee

The Nomination Committee will consist of the following persons who together represent 5,65 percent of the number of shares and votes in the Company as of September 30, 2024: The Nomination Committee will consist of the following persons who together represent 5,65 percent of the number of shares and votes in the Company as ofSeptember 30, 2024: Jeff Borcherding, the CEO of Immunovia AB, in his capacity as one of the company's largest shareholders, declined the opportunity to appoint a...
PR Newswire
08/01/2025

Abzena Strengthens Board with Appointment of Biopharma Industry Leader, Dr…

"I am thrilled to be joining Abzena's Board of Directors," said Slaoui. "Abzena is a true innovator in the CRO and CDMO space, and I look forward to helping them develop new technologies and platforms that enable the better delivery of next gen therapeutics." "I am thrilled to be joining Abzena's Board of Directors," said Slaoui. "Abzena is a true innovator in the CRO and CDMO space, and I look forward to helping them develop new technologies and platforms…
PR Newswire
08/01/2025

Hedia and Glooko Partner to Elevate Diabetes Management with Personalised Bolus…

A bolus is an extra amount of insulin taken to cover an expected rise in blood glucose, often related to a meal or snack.[1] Generally, to correct a high blood sugar, one unit of insulin is needed to drop the blood glucose by 50 mg/dl, however, this can vary across individuals.[2] For people with diabetes who do not have an insulin pump, calculating the appropriate bolus dose can present a challenge for them and their physicians. A bolus is an extra amount of insulin taken to cover an…
PR Newswire
08/01/2025

uniQure Announces Pricing of its Public Offering

Leerink Partners, Stifel and Guggenheim Securities are acting as the bookrunning managers for the offering. Chardan and H.C. Wainwright & Co. are acting as the lead managers for the offering.The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying...
Nasdaq GlobeNewswire
08/01/2025

MoonLake initiates three new clinical trials and further expands the portfolio…

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)MoonLake now independently running seven trials in 2025 across large dermatology and rheumatology indications: adult HS, adolescent HS, psoriatic arthritis (PsA), PPP and axSpAPhase 2 and Phase 3 data read-outs across all...
Nasdaq GlobeNewswire
08/01/2025

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

rdAnnual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30 AM EST).A live webcast of the presentation will be available on the Investors section of the Company's website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos Therapeutics, Inc.iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and...
Nasdaq GlobeNewswire
08/01/2025

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting…

The immune system plays a significant role in neurodegenerative diseases. In some, such as multiple sclerosis, it is the primary driver of the disease. In others, such as Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson disease, it has an amplifying role. Immunotherapeutic approaches that target the adaptive and innate immune systems are being explored for the treatment of almost all neurological diseases, and the targets and approaches are often common across diseases...
Nasdaq GlobeNewswire
08/01/2025

Valo Health and Novo Nordisk expand collaboration to discover and develop novel…

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular diseaseExpanded collaboration includes near-term payments totalling up to 190 million US dollars, while Valo is eligible to receive milestone payments of approximately 4.6billion dollars, plus R&D funding and potential royalty paymentsBagsværd, Denmark and Lexington,...
Nasdaq GlobeNewswire
08/01/2025
Altri  Comunicati